NCT01662505 2018-07-30
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Boehringer Ingelheim
Phase 1 Completed
Clinical Trials
3 trialsNCT02527174 2017-04-05
VIAC
University of Alberta
Phase 1 Withdrawn
NCT02722135 2017-01-27
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
Boehringer Ingelheim
Phase 1 Withdrawn